AXGN vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AXGN exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, and lacks an Altman Z-Score, limiting distress risk assessment. Despite strong revenue growth of 23.5% and improving profitability trends, the company remains unprofitable on a net basis with negative ROE and no meaningful cash flow data. Valuation metrics are stretched, with a high forward P/E of 65.88 and a Price/Book of 12.53, while insider selling of $10.58M in the last six months raises caution. Analysts maintain a strong_buy recommendation, but recent earnings volatility and lack of profitability temper bullish sentiment.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AXGN vs LLY: Head-to-Head Comparison
This page compares Axogen, Inc. (AXGN) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.